Next-Generation Sequencing in Thyroid Cancer

Molecular oncology is revolutionizing cancer care by using genetic profiling to tailor personalized treatments, improving efficacy, minimizing adverse events, and paving the way for advanced therapies.

In this episode of Targeted Talks, M. Michele Blackwood, MD, FACS, discusses the current landscape of breast cancer treatment and how personalized medicine with genomic testing is changing the field.

In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.

In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.

David Sallman, MD, Moffitt Cancer Center, discussed the trial's impact and the future role of MRD monitoring in treatment strategies for TP53-mutant MDS and AML.

Post-operative nivolumab significantly improved disease-free survival in resected locally advanced head and neck cancer, meeting the primary end point of the phase 3 NIVOPOSTOP trial.